A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
Status:
Terminated
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
Study Hypothesis: To estimate time to recurrence in pancreatic cancer patients treated with
adjuvant erlotinib and gemcitabine. Combination therapy will be given for 4 months followed
by single agent erlotinib for a total of 12 months.